Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Liver-resident antigen-presenting cells are a heterogeneous group of immune and non-immune cell types found in the liver, which process and present antigens to T cells. This group includes professional APCs such as dendritic cells, Kupffer cells (liver-resident macrophages), and B cells, as well as non-professional APCs like liver sinusoidal endothelial cells, hepatic stellate cells, and even hepatocytes. These cell types collectively maintain immune tolerance to gut-derived antigens and provide immune surveillance against pathogens; they also contribute to the regulation of local and systemic immune responses, including initiation of autoimmune hepatitis when tolerance is lost. "Liver-resident antigen-presenting cells" is not a single molecular target or protein, but rather a descriptive collective term, so it does not refer to a single canonical molecule or receptor[2][3][4][6]. The term "Liver-resident antigen-presenting cells" encompasses multiple cell types rather than a specific, singular molecule or protein, and therefore does not fit standard target definitions for drug discovery or therapeutic targeting. This makes it incorrect as a canonical individual molecular target[2][3][4]. These cells have crucial roles in immune tolerance, antigen presentation, and the balance between immunity and tolerance in the liver, with implications for infection (hepatitis viruses, malaria), autoimmune liver diseases (e.g., autoimmune hepatitis), cancer, and inflammation[2][3][4][5]. Drug and biomarker information do not apply to the group as a whole, only to specific receptors, proteins, or pathways expressed by individual subtypes (such as PD-L1 on Kupffer cells or LSECs), so these fields should be null for the collective description. There are no broadly recognized abbreviations for the collective group. For a structured database, this entry would be considered incorrect for a single target and would require breaking down into its constituent specific antigen-presenting cell types and their respective molecular features.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Liver-resident antigen-presenting cell.